KR100870284B1 - Ｄ３/ｄ２ 리셉터 길항물질로서의(티오)카르바모일-시클로헥산 유도체 - Google Patents

Ｄ３/ｄ２ 리셉터 길항물질로서의(티오)카르바모일-시클로헥산 유도체

Info

Publication number
KR100870284B1
KR100870284B1 KR1020067002364A KR20067002364A KR100870284B1 KR 100870284 B1 KR100870284 B1 KR 100870284B1 KR 1020067002364 A KR1020067002364 A KR 1020067002364A KR 20067002364 A KR20067002364 A KR 20067002364A KR 100870284 B1 KR100870284 B1 KR 100870284B1
Authority
KR
South Korea
Prior art keywords
ethyl
phenyl
trans
cyclohexyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067002364A
Other languages
English (en)
Korean (ko)
Other versions
KR20060058096A (ko
Inventor
에바 아게네 씨송올
자노스 갈람보스
카타린 노그라디
이스트반 바고
이스트반 기엘티안
벨라 키스
이스트반 라즈로브즈키
주디트 라스지
카탈린 사그히
Original Assignee
리히터 게데온 닐트.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리히터 게데온 닐트. filed Critical 리히터 게데온 닐트.
Publication of KR20060058096A publication Critical patent/KR20060058096A/ko
Application granted granted Critical
Publication of KR100870284B1 publication Critical patent/KR100870284B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020067002364A 2003-08-04 2004-05-21 Ｄ３/ｄ２ 리셉터 길항물질로서의(티오)카르바모일-시클로헥산 유도체 Expired - Lifetime KR100870284B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0302451 2003-08-04

Publications (2)

Publication Number Publication Date
KR20060058096A KR20060058096A (ko) 2006-05-29
KR100870284B1 true KR100870284B1 (ko) 2008-11-25

Family

ID=89981557

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067002364A Expired - Lifetime KR100870284B1 (ko) 2003-08-04 2004-05-21 Ｄ３/ｄ２ 리셉터 길항물질로서의(티오)카르바모일-시클로헥산 유도체

Country Status (36)

Country Link
US (2) US7737142B2 (https=)
EP (1) EP1663996B1 (https=)
JP (1) JP3999806B2 (https=)
KR (1) KR100870284B1 (https=)
CN (1) CN1829703B (https=)
AU (1) AU2004261490B2 (https=)
BE (1) BE2017C045I2 (https=)
BR (1) BRPI0413283B1 (https=)
CA (1) CA2532818C (https=)
CY (2) CY1113099T1 (https=)
DK (1) DK1663996T3 (https=)
EA (1) EA009022B1 (https=)
ES (1) ES2389840T3 (https=)
FR (1) FR17C0008I2 (https=)
HR (1) HRP20120715T1 (https=)
HU (2) HU227534B1 (https=)
IL (1) IL172746A (https=)
IS (1) IS2905B (https=)
LT (1) LTC1663996I2 (https=)
LU (1) LUC00039I2 (https=)
MA (1) MA28024A1 (https=)
ME (1) ME00564B (https=)
MX (1) MXPA06001033A (https=)
MY (1) MY142760A (https=)
NL (1) NL300913I2 (https=)
NO (2) NO334973B1 (https=)
NZ (1) NZ544999A (https=)
PL (1) PL1663996T3 (https=)
PT (1) PT1663996E (https=)
RS (1) RS52771B (https=)
SI (1) SI1663996T1 (https=)
TN (1) TNSN05328A1 (https=)
TW (1) TWI327141B (https=)
UA (1) UA84022C2 (https=)
WO (1) WO2005012266A1 (https=)
ZA (1) ZA200601026B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
MX2009004615A (es) * 2006-10-31 2009-05-22 Hoffmann La Roche Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).
HUP0700269A2 (en) * 2007-04-11 2009-04-28 Richter Gedeon Nyrt Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
ES2617671T3 (es) * 2007-05-11 2017-06-19 Richter Gedeon Nyrt. Forma cristalina de un derivado de carbamoil ciclohexano
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
CN101815519B (zh) * 2007-08-03 2013-08-21 吉瑞工厂 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
KR101563383B1 (ko) * 2008-02-21 2015-10-26 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
PL2317852T3 (pl) 2008-07-16 2015-05-29 Richter Gedeon Nyrt Preparaty farmaceutyczne zawierające ligandy receptora dopaminy
HU230067B1 (hu) * 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
HUP0900790A2 (en) 2009-12-17 2011-09-28 Richter Gedeon Nyrt A new process for the preparation of piperazine and their hydrochloric salts
CN103130737B (zh) * 2011-12-05 2015-12-02 江苏恒谊药业有限公司 环己烷胺类化合物及其作为抗精神分裂症药物的应用
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
WO2014059265A1 (en) * 2012-10-11 2014-04-17 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
CN105085345B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 含硝基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105085346B (zh) * 2015-08-14 2017-03-29 天津小新医药科技有限公司 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106518841B (zh) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
CN111925304A (zh) * 2015-09-22 2020-11-13 江苏恩华药业股份有限公司 一种用于制备卡利拉嗪的化合物及其制备方法
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
CN105330616B (zh) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
HU231173B1 (hu) 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN107793350B (zh) * 2016-09-05 2021-06-04 上海医药工业研究院 芳乙基哌啶基衍生物及其治疗精神分裂症的应用
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
EP3744721B1 (en) 2018-01-26 2025-07-02 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect
CN108586389B (zh) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 一种合成卡利拉嗪的方法
CN110872262A (zh) 2018-08-29 2020-03-10 上海科胜药物研发有限公司 一种卡利拉嗪的合成方法
CN110872269B (zh) * 2018-08-30 2024-06-07 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN110872270A (zh) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN111320594A (zh) * 2018-12-13 2020-06-23 江苏恩华药业股份有限公司 一种卡利拉嗪杂质及其制备工艺和用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) * 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
CN112239433B (zh) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
CN110372557B (zh) * 2019-08-06 2021-05-18 上海勋和医药科技有限公司 环己烷胺类d3/d2受体部分激动剂
AU2020376090A1 (en) * 2019-10-29 2022-04-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
JP7810643B2 (ja) * 2019-11-05 2026-02-03 上▲海▼翰森生物医▲薬▼科技有限公司 ベンゾチオフェン誘導体レギュレーター、その調製法及び使用
HUP2100108A1 (hu) 2021-03-12 2022-09-28 Richter Gedeon Nyrt Eljárás és berendezés gyógyászatilag alkalmazható piperazin származékok folyamatos áramú, áramlásos konszekutív redukálással történõ elõállítására
CA3216904A1 (en) 2021-04-28 2022-11-03 Jinyao CHEN Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
IL311268A (en) 2021-09-15 2024-05-01 Richter Gedeon Nyrt PROCESS TO PRODUCE (1r,4r)-4-SUBSTITUTED CYCLOHEXANE-1-AMINES
HU231682B1 (hu) 2022-08-05 2025-10-28 Richter Gedeon Nyrt. Kariprazin tartalmú szájban diszpergálódó tabletta
EP4594294A1 (en) * 2022-09-30 2025-08-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders
KR102921799B1 (ko) 2023-01-11 2026-02-04 리히터 게데온 닐트. 도파민 d3/d2 수용체 조절 화합물
CN118388432B (zh) * 2024-03-25 2025-07-18 成都奥邦药业有限公司 采用液相色谱法分离盐酸卡利拉嗪及其顺式异构体杂质的方法
EP4635946A1 (en) 2024-04-17 2025-10-22 F.I.S. Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of cariprazine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029233A1 (en) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. New sulfonamide derivatives as d3-receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
NZ525108A (en) 1998-03-31 2005-02-25 Acadia Pharm Inc Compounds with activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029233A1 (en) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. New sulfonamide derivatives as d3-receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal chemistry letters, 6(12), pp.1361-1366, 1996

Also Published As

Publication number Publication date
IL172746A0 (en) 2006-04-10
US7737142B2 (en) 2010-06-15
NL300913I1 (https=) 2017-11-23
MXPA06001033A (es) 2006-04-24
NZ544999A (en) 2009-07-31
HUS1700044I1 (hu) 2017-11-28
KR20060058096A (ko) 2006-05-29
DK1663996T3 (da) 2012-10-01
PT1663996E (pt) 2012-09-24
LTPA2017027I1 (lt) 2017-09-25
TWI327141B (en) 2010-07-11
HK1093494A1 (en) 2007-03-02
NL300913I2 (nl) 2017-12-20
AU2004261490B2 (en) 2008-08-21
CY2017032I2 (el) 2018-02-14
ES2389840T3 (es) 2012-11-02
HU0302451D0 (en) 2003-10-28
RS20060041A (sr) 2009-11-10
NO2017051I2 (no) 2018-11-19
CA2532818C (en) 2009-07-14
MY142760A (en) 2010-12-31
ME00564A (hr) 2011-12-20
RS52771B (sr) 2013-10-31
EP1663996A1 (en) 2006-06-07
US20060229297A1 (en) 2006-10-12
HU227534B1 (en) 2011-08-29
WO2005012266A1 (en) 2005-02-10
JP2007501215A (ja) 2007-01-25
IS2905B (is) 2014-10-15
TNSN05328A1 (en) 2007-07-10
CA2532818A1 (en) 2005-02-10
FR17C0008I2 (fr) 2018-12-07
NO20061076L (no) 2006-03-06
BRPI0413283B8 (pt) 2021-10-05
NO334973B1 (no) 2014-08-11
EP1663996B1 (en) 2012-06-20
NO2017051I1 (no) 2017-10-09
CN1829703B (zh) 2011-06-08
CN1829703A (zh) 2006-09-06
CY2017032I1 (el) 2018-02-14
ZA200601026B (en) 2007-05-30
MA28024A1 (fr) 2006-07-03
BRPI0413283A (pt) 2006-10-10
JP3999806B2 (ja) 2007-10-31
ME00564B (me) 2011-12-20
US20100240640A1 (en) 2010-09-23
BRPI0413283B1 (pt) 2021-10-05
EA200600364A1 (ru) 2006-06-30
AU2004261490A1 (en) 2005-02-10
BE2017C045I2 (https=) 2023-08-09
SI1663996T1 (sl) 2012-10-30
LTC1663996I2 (lt) 2018-05-25
UA84022C2 (ru) 2008-09-10
HRP20120715T1 (hr) 2012-09-30
FR17C0008I1 (fr) 2018-12-07
EA009022B1 (ru) 2007-10-26
PL1663996T3 (pl) 2012-11-30
TW200505874A (en) 2005-02-16
HUP0302451A2 (hu) 2005-05-30
CY1113099T1 (el) 2016-04-13
IL172746A (en) 2016-02-29
IS8199A (is) 2005-12-22
LUC00039I2 (https=) 2017-12-20
LUC00039I1 (https=) 2017-10-16

Similar Documents

Publication Publication Date Title
KR100870284B1 (ko) Ｄ３/ｄ２ 리셉터 길항물질로서의(티오)카르바모일-시클로헥산 유도체
US7705003B2 (en) Cyclohexylamides as dopamine D3, D2 and 5-HT1A Antagonists
US7473692B2 (en) Sulfonamide derivatives as D3-receptor ligands
US20050182111A1 (en) Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase
US4479954A (en) Piperazine substituted carboxamide derivatives, compositions and method of use
CN101528685A (zh) 作为缓激肽拮抗剂的新苯甲酰胺衍生物
EP0574808A1 (de) Amidin-Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HU222490B1 (hu) Eljárás hexahidroazepin-származékok és az ilyen vegyületeket tartalmazó gyógyászati készítmények előállítására
JP2011500782A (ja) ブラジキニンｂ１拮抗剤としての新規非ペプチド誘導体
EP1228053A1 (de) Substituierte piperazinderivate, ihre herstellung und ihre verwendung als inhibitoren des mikrosomalen triglyzerid-transferproteins (mtp)
NZ286340A (en) Amides of 2-(4-indolyl piperazia-1-yl)-1-ph-enyl (and bemzyl)ethyl amine derivatives with various (cyclo) alkane carboxylic acids; pharmaceutical compositions
HK1093494B (en) (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
CN102112466A (zh) 具有cb1-拮抗活性的(5r)-1，5-二芳基-4，5-二氢-1h-吡唑-3-甲脒衍生物
HK1114085A (en) Cyclohexylamides as dopamine d3, d2 and 5ht1a antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060907

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070813

Patent event code: PE09021S01D

AMND Amendment
AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20080205

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20080703

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080205

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20070813

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20080703

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080403

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071126

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071113

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070416

AMND Amendment
J121 Written withdrawal of request for trial
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080827

Appeal identifier: 2008101007227

Request date: 20080724

Patent event date: 20080724

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080703

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080724

Appeal identifier: 2008101007225

Request date: 20080724

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20080724

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2008101007225

Request date: 20080724

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080724

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080724

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080724

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080403

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20071126

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20071113

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070416

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20080827

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20080826

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20081119

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20081118

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110919

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20120920

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20120920

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130917

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130917

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140912

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140912

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20151002

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20151002

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160913

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160913

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20170928

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170928

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20180927

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180927

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20190919

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20190919

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20211111

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20221021

Start annual number: 15

End annual number: 15

PR1001 Payment of annual fee

Payment date: 20231006

Start annual number: 16

End annual number: 16

PC1801 Expiration of term

Termination date: 20241121

Termination category: Expiration of duration